The management of diabetes is progressing rapidly from the use of traditional finger sticks for glucose monitoring and multiple daily injections of insulin to more user-friendly devices and approaches. These advances hold the promise of freeing persons with diabetes from the need for continued daily compliance, thereby improving their quality of life and improving control of their underlying diabetes. An underlying theme to solutions based on percutaneous or fully implanted devices is that the useful lifetime of such devices is often limited by the body's foreign body response. This review briefly outlines general factors associated with point-in-time needle stick approaches to the growing use of short-term percutaneous implants (≤7 days) to the challenges of more extended devices, both technical and regulatory, faced by developers of these devices.
AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13Suppl 1: 1–68.
2.
FunnellMMAndersonRM.MSJAMA: the problem with compliance in diabetes. JAMA. 2000;284 (13): 1709.
3.
KorytkowskiMNiskanenLAsakuraT.FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27Suppl B: S89–100.
4.
BaumCLArpeyCJ.Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol Surg. 2005;31 (6): 674–86; discussion 686.
5.
GretzerCEmanuelssonLLiljenstenEThomsenP.The inflammatory cell influx and cytokines changes during transition from acute inflammation to fibrous repair around implanted materials. J Biomater Sci Polym Ed. 2006;17 (6): 669–87.
6.
SharkawyAAKlitzmanBTruskeyGAReichertWM.Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J Biomed Mater Res. 1997;37 (3): 401–12.
7.
FeldmanBBrazgRSchwartzSWeinsteinR.A continuous glucose sensor based on wired enzyme technology—results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5 (5): 769–79.
8.
BodeBGrossKRikaloNSchwartzSWahlTPageCGrossTMastrototaroJ.Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther. 2004;6 (2): 105–13.
9.
RebrinKSteilGMvan AntwerpWPMastrototaroJJ.Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol. 1999;277 (3Pt 1): E561–71.
10.
Djakouré-PlatonoffCRadermerckerRReachGSlamaGSelamJI.Accuracy of the continuous glucose monitoring system in inpatient and outpatient conditions. Diabetes Metab. 2003;29 (2Pt 1): 159–62.
11.
TanenbergRBodeBLaneWLevetanCMestmanJHarmelAPTobianJGrossTMastrototaroJ.Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79 (12): 1521–6.
12.
GargSKSchwartzSEdelmanSV.Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004;27 (3): 734–8.
13.
ZickRPetersenBRichterMHaugC; SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther. 2007;9 (6): 483–92.
14.
Tubiana-RufiNRivelineJPDardariD.Real-time continuous glucose monitoring using GuardianRT: from research to clinical practice. Diabetes Metab. 2007;33 (6): 415–20.
15.
ParknerTLaursenTVestergaardETHartvigHSmedegaardJSLauritzenTChristiansenJS.Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes. Diabet Med. 2008;25 (5): 585–91.
16.
Opipari-ArriganLFredericksEMBurkhartNDaleLHodgeMFosterC.Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes. 2007;8 (6): 377–83.
17.
ZisserHCBevierWCJovanovicL.Restoring euglycemia in the basal state using continuous glucose monitoring in subjects with type 1 diabetes mellitus. Diabetes Technol Ther. 2007;9 (6): 509–15.
18.
Hanaire-BroutinHMelkiVBessières-LacombeSTauberJP.Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care. 2000;23 (9): 1232–5.
19.
ScrimgeourLCobryEMcFannKBurdickPWeimerCSloverRChaseHP.Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes. Diabetes Technol Ther. 2007;9 (5): 421–8.
20.
AlemzadehRPalma-SistoPHolzumMPartonEKicherJ.Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. Diabetes Technol Ther. 2007;9 (4): 339–47.
21.
RabboneIBobbioABergerKTradaMSacchettiCCeruttiF.Age-related differences in metabolic response to continuous subcutaneous insulin infusion in pre-pubertal and pubertal children with Type 1 diabetes mellitus. J Endocrinol Invest. 2007;30 (6): 477–83.
22.
DoyleEAWeinzimerSASteffenATAhernJAVincentMTamborlaneWV.A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27 (7): 1554–8.
23.
HenchLEthridgeE.Biomaterials, an interfacial approach. San Diego: Academic Press; 1982.
24.
KasemoBGoldJ.Implant surfaces and interface processes. Adv Dent Res. 1999;13: 8–20.
25.
NortonLWKoschwanezHEWisniewskiNAKlitzmanBReichertWM.Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. J Biomed Mater Res A. 2007;81 (4): 858–69.
26.
SharkawyAAKlitzmanBTruskeyGAReichertWM.Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. J Biomed Mater Res. 1998;40 (4): 586–97.
27.
SharkawyAAKlitzmanBTruskeyGAReichertWM.Engineering the tissue which encapsulates subcutaneous implants. III. Effective tissue response times. J Biomed Mater Res. 1998;40 (4): 598–605.
28.
WardWKSlobodzianEPTiekotterKLWoodMD.The effect of microgeometry, implant thickness and polyurethane chemistry on the foreign body response to subcutaneous implants. Biomaterials. 2002;23 (21): 4185–92.
29.
PichaGJDrakeRF.Pillared-surface microstructure and soft-tissue implants: effect of implant site and fixation. J Biomed Mater Res. 1996;30 (3): 305–12.
30.
SmahelJHurwitzPJHurwitzN.Soft tissue response to textured silicone implants in an animal experiment. Plast Reconstr Surg. 1993;92 (3): 474–9.
BraukerJHCarr-BrendelVEMartinsonLACrudeleJJohnstonWDJohnsonRC.Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res. 1995;29 (12): 1517–24.
34.
BraukerJJohnsonRMartinsonLHillR. United States patent US 5,964,804. 1995 Jun 7.
35.
DalbyMJRiehleMOJohnstoneHAffrossmanSCurtisAS.In vitro reaction of endothelial cells to polymer demixed nanotopography. Biomaterials. 2002;23 (14): 2945–54.
36.
GilliganBCShultsMRhodesRKJacobsPGBraukerJHPintarTJUpdikeSJ.Feasibility of continuous long-term glucose monitoring from a subcutaneous glucose sensor in humans. Diabetes Technol Ther. 2004;6 (3): 378–86.
37.
PonderSWSkylerJSKrugerDFMathesonDBrownBW.Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment. Diabetes Educ. 2008;34 (2): 327–33.
RadermeckerRPPiérardGEScheenAJ.Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8 (1): 21–8.
40.
Del OlmoMICamposVAbellánPMerino-TorresJFPiñónF.A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract. 2008;80 (1): e20–1.
41.
SaudekCD.Implantable insulin infusion pumps: a case presentation. Diabetes Educ. 1989;15 (1): 44–9.
42.
SaudekCDSelamJLPittHAWaxmanKRubioMJeandidierNTurnerDFischellRECharlesMA.A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. 1989;321 (9): 574–9.
43.
UdelsmanRChenHLomanKPittHASaudekCD.Implanted programmable insulin pumps: one hundred fifty-three patient years of surgical experience. Surgery. 1997;122 (6): 1005–11.
44.
GinHRenardEMelkiVBoivinSSchaepelynck-BélicarPGuerciBSelamJLBrunJMRivelineJPEstourBCatargiB; EVADIAC Study Group. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003;29 (6): 602–7.
45.
Hanaire-BroutinHBroussolleCJeandidierNRenardEGuerciBHaardtMJLassmann-VagueV.Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care. 1995;18 (3): 388–92.
